Although there has been a report showing that METTL3 impairs ccRCC progression in Caki-1 and Caki-2 cell lines through epithelial to-mesenchymal transition (EMT) and PI3K-Akt-mTOR pathways (Li et al., 2017), other studies identified METTL3 predicts a poor overall survival of ccRCC patients in TCGA datasheet (Chen et al., 2020; Zheng et al., 2020), implying that METTL3 might be an oncogene. Here, MTOR is linked to nonpapillary renal cell carcinoma.